However, it has been shown that the treatment of MS patients with IFN-β reduces the levels of DRD5 and abolishes the expression of the machinery required to synthesise dopamine in Tregs, thus re-establishing their suppressive activity (35). The gene discussed is IFNB1; the disease is myeloid sarcoma.